Y15-FAK-inhibitor-Y15-DataSheet-生命科学试剂-MedChemExpressVIP

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEY15Cat. No.: HY-12444CAS No.: 4506-66-5Synonyms: FAK inhibitor Y15; FAK Inhibitor 14分式: CHClN分量: 284.01作靶点: FAK作通路: Protein Tyrosine Kinase/RTK储存式: 4C, sealed storage, away from moisture* In solvent : -80C, 6 months; -20C, 1 mon

2、th (sealedstorage, away from moisture)溶解性数据体外实验 H2O : 59 mg/mL (207.74 mM; Need ultrasonic and warming)Mass Solvent1 mg 5 mg 10 mg Concentration制备储备液1 mM 3.5210 mL 17.6050 mL 35.2100 mL5 mM 0.7042 mL 3.5210 mL 7.0420 mL10 mM 0.3521 mL 1.7605 mL 3.5210 mL请根据产品在不同溶剂中的溶解度，选择合适的溶剂配制储备液，并请注意储备液的保存式和期限。BI

3、OLOGICAL ACTIVITY物活性 Y15种有效，特异性的粘 斑激酶抑制剂 (FAK)，可抑制其磷酸化活性，降低癌细胞的活，阻断肿瘤长。IC50 & Target FAK 1体外研究Y15 directly blocks autophosphorylation activity of FAK. Y15 inhibits Y397 phosphorylation of FAK starting at0.1 M in Panc-1 cells. At a dose of 100 M, Y15 has the same or better inhibition as TAE226. Of no

4、te, total1/3 Master of Small Molecules 您边的抑制剂师www.MedChemEFAK is downregulated at higher doses of Y15. Y15 also blocks phosphorylation of the FAK downstreamsubstrate, paxillin. Total paxillin is decreased at higher doses similar to FAK. Thus, Y15 inhibits FAKphosphorylation in a dose-dependent manne

5、r 1. MTS assay is completed using a range of Y15 doses on allcell lines (TT, K1, BCPAP, and TPC1, respectively).Y15 inhibited cell viability in a dose-dependent manneracross all thyroid cell lines evaluated. IC50 is 2.05, 5.74, 9.99, and 17.54 M for TT, TPC1, BCPAP, and K1,respectively 2.体内研究 Nude m

6、ice bearing Panc si-ctrl xenografts are treated with TAE226, a dual FAK and IGF-1R tyrosine kinaseinhibitor, to provide a reference for the antitumor effect of dual inhibition of FAK and IGF-1R. Without drugtreatment, Panc si5-IGF-1R xenografts grew slower than Panc si-ctrl xenografts (Panc si5-IGF-

7、1R/PBS vs.Panc si-ctrl/PBS), suggesting moderate tumor suppression by inhibiting the IGF-1R pathway only. Furtherinhibition of FAK activity by Y15 treatment suppresses the growth of Panc si5-IGF-1R xenografts moredrastically (Panc si5-IGF-1R/PBS vs. Panc si5-IGF-1R/Y15). A similar antitumor effect i

8、s seen in Panc si-ctrlxenografts treated with TAE226 (Panc si5-IGF-1R/Y15 vs. Panc si-ctrl/TAE226). Mice demonstrates normalgrooming and eating habits throughout the experiment 3.PROTOCOLKinase Assay 1 10 Ci of -32P-ATP in a kinase buffer 20 mM HEPES, pH 7.4, 5 mM MgCl2, 5 mM MnCl2, 0.1 mMNa3VO4 wit

9、h 0.1 g of purified FAK protein are incubated in a kinase buffer with 10 Ci of -32P-ATP. Thekinase reaction is performed for 5 minutes at room temperature and stopped by addition of 2 Laemmlibuffer. Proteins are separated on a Ready SDS-10% PAGE gel, and the phosphorylated enolase isvisualized by au

10、toradiography 1MCE has not independently confirmed the accuracy of these methods. They are for reference only.Cell Assay 1 The cells are treated with Y15 or TAE226 at different concentrations for 24 hours. The 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium c

11、ompound from Promega Viability kit isadded, and the cells are incubated at 37C for 1-2 hours. The optical density on 96-plate is analyzed with amicroplate reader at 490 nm to determine cell viability. In addition, cells are stained with trypan blue after 24hours of treatment with Y15 and the percent

12、 of cells that stained positive are determined with ahemacytometer 1MCE has not independently confirmed the accuracy of these methods. They are for reference only.Animal Mice 3Administration 3 Six-week-old, female nude mice are used. 5106 Panc si5-IGF-1R cells are mixed with matrigel and injectedsub

13、cutaneously into the flank of athymic nude mice (day 0). Animals are randomly divided into two groups onday 7. One group (n=5) received Y15 (30 mg/kg) and the other received PBS as control treatment (n=5). ForPanc si-ctrl xenografts, 5106 Panc si-ctrl cells are mixed with matrigel and injected subcu

14、taneously into theflank of nude mice. These animals are also randomly divided into two groups on day 7, and one group (n=5)received TAE226 (30 mg/kg), the other group received PBS (n=5) as control treatment. The drugs and PBSare administered through intraperitoneal injection in a total volume of 0.1

15、 mL. Tumor sizes are measuredevery 3 or 4 d in length (mm)width (mm) starting from day 10. Tumor volume is calculated as volume(cm3)= 1/2length (cm)width(cm)2.2/3 Master of Small Molecules 您边的抑制剂师www.MedChemEMCE has not independently confirmed the accuracy of these methods. They are for reference on

16、ly.户使本产品发表的科研献 Acta Biochim Biophys Sin (Shanghai). 2018 Oct 1;50(10):976-983. Oncotarget. 2017 Oct 5;8(56):95586-95595.See more customer validations on HYPERLINK / www.MedChemEREFERENCES1. Hochwald SN, et al. A novel small molecule inhibitor of FAK decreases growth of human pancreatic cancer. Cell

17、Cycle. 2009Aug;8(15):2435-43.2. OBrien S, et al. FAK inhibition with small molecule inhibitor Y15 decreases viability, clonogenicity, and cell attachment in thyroid cancercell lines and synergizes with targeted therapeutics. Oncotarget. 2014 Sep 15;5(17):7945-59.3. Zheng D, et al. A novel strategy to inhibit FAK and IGF-1R decreases growth of pancr